On October 12, 2026, the Stochastic Oscillator for AORT moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 53 instances where the indicator left the oversold zone. In 42 of the 53 cases the stock moved higher in the following days. This puts the odds of a move higher at over 79%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AORT's RSI Oscillator exited the oversold zone, 17 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for AORT just turned positive on October 14, 2026. Looking at past instances where AORT's MACD turned positive, the stock continued to rise in 36 of 48 cases over the following month. The odds of a continued upward trend are 75%.
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where AORT advanced for three days, in 222 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The 10-day moving average for AORT crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AORT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for AORT entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. AORT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.511) is normal, around the industry mean (10.930). P/E Ratio (104.680) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (4.200) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.603) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AORT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
LMAT saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 105 similar instances where the indicator turned positive. In 78 of the 105 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.
LMAT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMAT advanced for three days, in 230 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
LMAT broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LMAT entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.480) is normal, around the industry mean (5.011). P/E Ratio (28.790) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (2.178) is also within normal values, averaging (4.456). Dividend Yield (0.012) settles around the average of (0.005) among similar stocks. P/S Ratio (7.267) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. LMAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
AORT | LMAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 57 | |
SMR RATING 1..100 | 91 | 52 | |
PRICE GROWTH RATING 1..100 | 81 | 62 | |
P/E GROWTH RATING 1..100 | 88 | 77 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LMAT's Valuation (15) in the Medical Specialties industry is significantly better than the same rating for AORT (92). This means that LMAT’s stock grew significantly faster than AORT’s over the last 12 months.
LMAT's Profit vs Risk Rating (57) in the Medical Specialties industry is somewhat better than the same rating for AORT (100). This means that LMAT’s stock grew somewhat faster than AORT’s over the last 12 months.
LMAT's SMR Rating (52) in the Medical Specialties industry is somewhat better than the same rating for AORT (91). This means that LMAT’s stock grew somewhat faster than AORT’s over the last 12 months.
LMAT's Price Growth Rating (62) in the Medical Specialties industry is in the same range as AORT (81). This means that LMAT’s stock grew similarly to AORT’s over the last 12 months.
LMAT's P/E Growth Rating (77) in the Medical Specialties industry is in the same range as AORT (88). This means that LMAT’s stock grew similarly to AORT’s over the last 12 months.
| AORT | LMAT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | N/A |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 61% |
| Momentum ODDS (%) | N/A | 1 day ago 74% |
| MACD ODDS (%) | 1 day ago 75% | N/A |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 68% |
| Advances ODDS (%) | 3 days ago 74% | 3 days ago 68% |
| Declines ODDS (%) | 7 days ago 67% | 13 days ago 54% |
| BollingerBands ODDS (%) | N/A | 1 day ago 58% |
| Aroon ODDS (%) | 1 day ago 74% | 1 day ago 62% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AORT’s FA Score shows that 0 FA rating(s) are green while LMAT’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AORT’s TA Score shows that 4 TA indicator(s) are bullish while LMAT’s TA Score has 3 bullish TA indicator(s).
AORT (@Medical/Nursing Services) experienced а -0.37% price change this week, while LMAT (@Pharmaceuticals: Other) price change was +4.17% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.79%. For the same industry, the average monthly price growth was -7.51%, and the average quarterly price growth was -14.87%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.96%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +3.79%.
AORT is expected to report earnings on Oct 29, 2026.
LMAT is expected to report earnings on Nov 04, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-0.96% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor indicates that over the last year, LMAT has been loosely correlated with ITGR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LMAT jumps, then ITGR could also see price increases.
| Ticker / NAME | Correlation To LMAT | 1D Price Change % | ||
|---|---|---|---|---|
| LMAT | 100% | +1.31% | ||
| ITGR - LMAT | 48% Loosely correlated | +0.02% | ||
| SYK - LMAT | 46% Loosely correlated | -0.33% | ||
| UFPT - LMAT | 44% Loosely correlated | -1.08% | ||
| AORT - LMAT | 40% Loosely correlated | +0.80% | ||
| RDNT - LMAT | 39% Loosely correlated | -3.29% | ||
More | ||||